Glaxo 'downplayed' warning on heart-attack risk from Aids drug

The multinational drugs company GlaxoSmithKline (GSK) downplayed an early warning about the rising number of people who have suffered potentially fatal heart attacks following the use of its £600m anti-Aids drug, which is taken daily by tens of thousands of people around the world.

GSK was officially told of the possible risk in May 2005, three years before it issued a statement to its investors saying that the findings of an even stronger potential link between heart attacks and its antiviral drug abacavir are both “unexpected” and “unconfirmed”.

The company also said that it could find no association between abacavir use and heart attacks following a trawl through its internal data, however it failed to mention that its own summary of product characteristics issued when the drug was launched in the late 1990s had actually described “mild myocardial degeneration” in the hearts of mice and rats given the drug for two years.

Some scientists involved with monitoring the safety of Aids drugs are privately furious with GSK for downplaying the significance of one of the biggest safety trials into abacavir – one of several anti-viral drugs taken by Aids patients as part of combined HIV therapy – when the findings were published last month.

“GSK was extraordinarily well prepared in terms of a statement that downplayed the significance of the findings,” said one of the scientists close to the safety study.

“As a consequence, people are now confused and perplexed because they think there is something wrong with the study itself because GSK said that it cannot find any evidence to support the findings of a link with myocardial infarction [heart attacks],” he said.

Alastair Benbow, European medical director for GSK, said that the company takes any new information about the safety of its drugs seriously but it did not want to highlight what may be “spurious observations” relating to abacavir.

The first public sign that abacavir may be linked with increased risk of heart attacks emerged this April when The Lancet published the worldwide “DAD” study into the adverse reactions to anti-HIV drugs, involving clinical observations of 33,347 Aids patients across Europe, Australia and the United States.

The study found that the risk of having a heart attack in patients taking abacavir was almost double that of HIV patients who did not take the drug as part of their combination therapy. The study also found that the risk of heart attacks returned to normal six months after they had stopped taking abacavir.

Independent scientists who analysed the DAD findings said in The Lancet that the data were not strong enough to establish a causal connection because that would have required a different type of study; but they emphasised that the observed increase in the risk of heart attacks was “too strong to ignore”.

The same scientists also pointed out that the studies on which GSK relied for casting doubt on the DAD study were themselves not powerful enough to discount a link between the drug and the risk of heart attacks.

To coincide with the Lancet publication, GSK issued a statement to its investors playing down the association between abacavir and heart attacks, saying that the findings of the DAD study were unexpected and that no possible biological mechanism to explain it has been found.

The statement did not mention that GSK had been made aware three years earlier of a report involving 34 cases of heart attacks in patients taking abacavir. The report or “signal” was sent to the company in May 2005 by an international drug-monitoring centre operated by the WHO in Uppsala, Sweden.

“We sent them the signal and we gave them the chance to comment on it. We received a reply, which was in effect a no-reply. They said ‘thank-you’ and that was all,” said Dr Ralph Edwards, director of the Uppsala Monitoring Centre.

“The purpose of our signal was to do exactly that, to make them aware that there is at least a risk. We expect countries and companies to take it seriously. I am disappointed with GSK’s response in the published literature,” Dr Edwards said.

Dr Benbow said that GSK investigated the Uppsala signal in 2005 and carried out a check of its own internal data, as well as the database of the American Food and Drug Administration, but could not replicate the finding. “So there was not a signal in our internal database or that of the FDA,” he said.

Didier Lapierre, GSK’s vice president of clinical development, said in the statement to investors at the time of the April DAD study that the increased relative risk of heart attacks remained low in absolute terms and that patients should not discontinue treatment without medical advice.

“The DAD findings are unexpected, since we have not seen similar findings in our studies, and we are unaware of any potential biological mechanism that would explain them. In our own analysis of trials involving more than 9,600 patients, no increased risk of heart attack associated with abacavir was found,” Dr Lapierre said.

Scientists involved in the DAD study, however, believe that a possible biological mechanism is that abacavir is converted into a potentially toxic substance called carbovir once it gets into the cells of the heart.

They cite GSK’s own research on animals in support of this hypothesis which found that abacavir is associated with mild myocardial degeneration in the heart tissue of rats and mice given the drug for a period of two years. Dr Benbow said that the company has investigated this hypothesis but has not found any data to support it.

However, Professor Jens Lundgren of Copenhagen University, who led the DAD study, said that his team is actively pursuing this proposal as a possible explanation for the doubling of the risk of heart attacks seen in abacavir patients.

“We do have a sense of what could be the problem. However, we were completely crushed in the GSK media machine when our study came out. GSK were made aware of the findings at the end of last year when we had the first meetings with them,” Professor Lundgren said.

The US Federal Drug Administration and the European Medicines Agency have both said that at present there is no reason to change the prescribing information for abacavir, however they are both reviewing the safety data on abacavir in relation to heart attacks and are expected to issue their conclusions and recommendations later this year.

Suggested Topics
News
The clocks go forward an hour at 1am on Sunday 30 March
news
Arts and Entertainment
The Doctor finds himself in a forest version of London in Doctor Who episode 'In the Forest of the Night'
TVReview: Is the Doctor ever going stop frowning? Apparently not.
Sport
footballMatch report: Real fight back to ruin Argentinian's debut
News
Bruce, left, with Cream bandmates Ginger Rogers, centre, and Eric Clapton in 1967
people
PROMOTED VIDEO
News
ebooksAn unforgettable anthology of contemporary reportage
Money
Welcome to tinsel town: retailers such as Selfridges will be Santa's little helpers this Christmas, working hard to persuade shoppers to stock up on gifts
news
News
i100
News
people
Arts and Entertainment
Architect Frank Gehry is regarded by many as the most important architect of the modern era
arts + entsGehry has declared that 98 per cent of modern architecture is "s**t"
Arts and Entertainment
Soul singer Sam Smith cleared up at the Mobo awards this week
arts + entsSam Smith’s Mobo triumph is just the latest example of a trend
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs General

Maths Teacher

£110 - £200 per day: Randstad Education Leeds: Secondary Maths Teacher for spe...

Business Analyst - Surrey - Permanent - Up to £50k DOE

£40000 - £50000 Per Annum Excellent benefits: Clearwater People Solutions Ltd:...

***ASP.NET Developer - Cheshire - £35k - Permanent***

£30000 - £35000 Per Annum Excellent benefits: Clearwater People Solutions Ltd:...

***Solutions Architect*** - Brighton - £40k - Permanent

£35000 - £40000 Per Annum Excellent benefits: Clearwater People Solutions Ltd:...

Day In a Page

Wilko Johnson, now the bad news: musician splits with manager after police investigate assault claims

Wilko Johnson, now the bad news

Former Dr Feelgood splits with manager after police investigate assault claims
Mark Udall: The Democrat Senator with a fight on his hands ahead of the US midterm elections

Mark Udall: The Democrat Senator with a fight on his hands

The Senator for Colorado is for gay rights, for abortion rights – and in the Republicans’ sights as they threaten to take control of the Senate next month
New discoveries show more contact between far-flung prehistoric humans than had been thought

New discoveries show more contact between far-flung prehistoric humans than had been thought

Evidence found of contact between Easter Islanders and South America
Cerys Matthews reveals how her uncle taped 150 interviews for a biography of Dylan Thomas

Cerys Matthews on Dylan Thomas

The singer reveals how her uncle taped 150 interviews for a biography of the famous Welsh poet
DIY is not fun and we've finally realised this as a nation

Homebase closures: 'DIY is not fun'

Homebase has announced the closure of one in four of its stores. Nick Harding, who never did know his awl from his elbow, is glad to see the back of DIY
The Battle of the Five Armies: Air New Zealand releases new Hobbit-inspired in-flight video

Air New Zealand's wizard in-flight video

The airline has released a new Hobbit-inspired clip dubbed "The most epic safety video ever made"
Pumpkin spice is the flavour of the month - but can you stomach the sweetness?

Pumpkin spice is the flavour of the month

The combination of cinnamon, clove, nutmeg (and no actual pumpkin), now flavours everything from lattes to cream cheese in the US
11 best sonic skincare brushes

11 best sonic skincare brushes

Forget the flannel - take skincare to the next level by using your favourite cleanser with a sonic facial brush
Paul Scholes column: I'm not worried about Manchester United's defence - Chelsea test can be the making of Phil Jones and Marcos Rojo

Paul Scholes column

I'm not worried about Manchester United's defence - Chelsea test can be the making of Jones and Rojo
Frank Warren: Boxing has its problems but in all my time I've never seen a crooked fight

Frank Warren: Boxing has its problems but in all my time I've never seen a crooked fight

While other sports are stalked by corruption, we are an easy target for the critics
Jamie Roberts exclusive interview: 'I'm a man of my word – I'll stay in Paris'

Jamie Roberts: 'I'm a man of my word – I'll stay in Paris'

Wales centre says he’s not coming home but is looking to establish himself at Racing Métro
How could three tourists have been battered within an inch of their lives by a burglar in a plush London hotel?

A crime that reveals London's dark heart

How could three tourists have been battered within an inch of their lives by a burglar in a plush London hotel?
Meet 'Porridge' and 'Vampire': Chinese state TV is offering advice for citizens picking a Western moniker

Lost in translation: Western monikers

Chinese state TV is offering advice for citizens picking a Western moniker. Simon Usborne, who met a 'Porridge' and a 'Vampire' while in China, can see the problem
Handy hacks that make life easier: New book reveals how to rid your inbox of spam, protect your passwords and amplify your iPhone

Handy hacks that make life easier

New book reveals how to rid your email inbox of spam, protect your passwords and amplify your iPhone with a loo-roll
KidZania lets children try their hands at being a firefighter, doctor or factory worker for the day

KidZania: It's a small world

The new 'educational entertainment experience' in London's Shepherd's Bush will allow children to try out the jobs that are usually undertaken by adults, including firefighter, doctor or factory worker